The study of once- and twice-daily biphasic insulin aspart 30 (BIAsp 30) with sitagliptin, and twice-daily BIAsp 30 without sitagliptin, in patients with type 2 diabetes uncontrolled on sitagliptin and metformin—The Sit2Mix trial
| Autor: | Radhakrishna Sothiratnam, Sultan Linjawi, Paturi Rao, Line Conradsen Hiort, Ramazan Sari, Henning F. Andersen |
|---|---|
| Jazyk: | angličtina |
| Předmět: |
Blood Glucose
Male Time Factors Sitagliptin Phosphate/administration & dosage Endocrinology Diabetes and Metabolism Cost-Benefit Analysis Insulin Isophane Biphasic Insulins/administration & dosage Type 2 diabetes law.invention Metformin/administration & dosage Randomized controlled trial law Biphasic insulin Nutrition and Dietetics Middle Aged Metformin Europe Treatment Outcome Tolerability Sitagliptin Drug Therapy Combination Female Randomized trial Family Practice Diabetes Mellitus Type 2/blood medicine.drug medicine.medical_specialty Asia Glycated Hemoglobin A/metabolism Biphasic Insulins Drug Administration Schedule Drug Costs Insulin Isophane/administration & dosage Blood Glucose/drug effects Diabetes mellitus Internal medicine Internal Medicine medicine Hypoglycemic Agents Humans In patient Insulin Aspart/administration & dosage Insulin Aspart Aged Glycated Hemoglobin business.industry Sitagliptin Phosphate Australia South America medicine.disease Hypoglycemic Agents/administration & dosage Biphasic insulin aspart Endocrinology Diabetes Mellitus Type 2 business Biomarkers Biomarkers/blood |
| Zdroj: | Linjawi, S, Sothiratnam, R, Sari, R, Andersen, H, Hiort, L C & Rao, P 2015, ' The study of once-and twice-daily biphasic insulin aspart 30 (BIAsp 30) with sitagliptin, and twice-daily BIAsp 30 without sitagliptin, in patients with type 2 diabetes uncontrolled on sitagliptin and metformin-The Sit2Mix trial ', Primary care diabetes, vol. 9, no. 5, pp. 370-6 . https://doi.org/10.1016/j.pcd.2014.11.001 |
| ISSN: | 1751-9918 |
| DOI: | 10.1016/j.pcd.2014.11.001 |
| Popis: | AIMS: Investigate efficacy and tolerability of intensifying diabetes treatment with once- or twice-daily biphasic insulin aspart 30 (BIAsp 30) added to sitagliptin, and twice-daily BIAsp 30 without sitagliptin in patients with type 2 diabetes (T2D) inadequately controlled on sitagliptin.METHODS: Open-label, three-arm, 24-week trial; 582 insulin-naïve patients were randomized to twice-daily BIAsp 30+sitagliptin (BIAsp BID+Sit), once-daily BIAsp 30+sitagliptin (BIAsp QD+Sit) or twice-daily BIAsp 30 without sitagliptin (BIAsp BID), all with metformin.RESULTS: After 24 weeks, HbA1c reduction (%) was superior with BIAsp BID+Sit vs. BIAsp QD+Sit (BIAsp BID+Sit minus BIAsp QD+Sit difference: -0.36 [95% CI -0.54; -0.17], PCONCLUSIONS: Adding BIAsp 30 to patients with T2D poorly controlled with sitagliptin and metformin is efficacious and well tolerated; however, while BIAsp BID+Sit showed superior glycaemic control, BIAsp QD+Sit had a lower rate of hypoglycaemia and showed no weight gain. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|